NephCure Kidney International ®

Saving Kidneys, Saving Lives

  • Find a Specialist
  • Find a Clinical Trial
  • Donate
  • Living with Kidney Disease
    • Understanding Kidney Disease
    • Understanding Nephrotic Syndrome and Glomerular Disease
    • Treatment Options
    • Managing Your Care
    • Diet and Nutrition
    • Resources A-Z
    • Educational Programs
    • End Stage Renal Disease
    • Just for Kids!
  • Patient Connections
    • Patient Stories
    • Share Your Story
    • NephSpace – Our Online Support Community
    • Patient Support
  • Events
  • Get Involved
    • Join Your Local Community
    • Participate in Research
    • Advocacy
    • Peer Support
    • Donate
  • Research
    • Get Involved in Research
    • Conferences and Meetings
    • Apply for Research Grants
  • About Us
    • Recent News
    • Funded Research
    • Staff
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Partners
  • Donate
    • One Time Donation
    • Give Monthly
    • Donate to an Event

First ever Phase 3 Trial for FSGS now enrolling

July 31, 2018 by Rebecca Cook

Filed Under: Uncategorized Tagged With: Clinical Trial, Research, Research News

The FIRSTx Clinical Trial

May 18, 2018 by Chelsey Fix

About the FIRSTx Clinical Trial

FIRSTx is a Phase 2 study testing the safety and effectiveness of an investigational drug called CXA-10 designed to treat FSGS without steroids. This study will see if CXA-10 can reduce proteinuria while maintaining stable kidney function in people with FSGS. Throughout the course of the study, researchers will measure how different doses of CXA-10 impact proteinuria and carefully evaluate the kidney related and other effects of CXA-10. The study is taking place at approximately 20 centers across the United States.

How To Contact a Study Center:

  • Call 844-618-2479
  • Click here for study website 
  • Email FIRSTx_Trial@med.umich.edu

About CXA-10

Animal studies suggest that CXA-10 appears to work by reducing inflammation in the glomeruli and helping to prevent scarring. CXA-10 has been evaluated in healthy volunteers. CXA-10 will be provided to study participants in the form of a pill taken once a day in the morning with food.

Learn more about The FirstX Clinical Trial by clicking here.

Click here to learn more about research and clinical trials 

Check out recent Research News

Filed Under: Uncategorized Tagged With: Clinical Trial, Research, Research News

DUET Study Releases Preliminary Results (SPOILER it looks promising!)

September 7, 2016 by Chelsey Fix

big-newsOn September 7, 2016, Retrophin Inc. released the “Top Line” results from their recently completed DUET study, a Phase 2 clinical trial testing safety and efficacy of Sparsentan for FSGS patients.

Results showed promise for Sparsentan’s effectiveness at reducing proteinuria in patients with FSGS, with one group of patients seeing an average reduction of 44.8%. The DUET study included 96 patients, and only one serious adverse side effect (anemia) was reported. All patients chose to extend their treatment with Sparsentan during the trial’s open label extension period.

Alvin Shih MD, the executive vice-president for Retrophin Inc., said “significant reductions in proteinuria, along with a well-tolerated preliminary safety profile have us excited about being one step closer to providing a new treatment option for patients with FSGS.”

NephCure Kidney International is excited about these results and support Dr. Shih’s hope that we are moving closer to providing a new, effective, and safe treatment option for FSGS patients. Mark Stone, Chief Executive Officer of NephCure Kidney International, remarked “These preliminary results are very exciting for our community. This gives us hope that better treatment options will be available for our families in the near future.”

NephCure Kidney International would like to thank everyone who contributed time, talent, and resources to this study.  Thank you, especially, to the patients and families who participated and helped bring effective treatments within reach.

Read the official press release here

DUET-logo-for-web

Retrophin company logo

 

Filed Under: Uncategorized Tagged With: awareness, Clinical Trial, Cures, Drug Trial, DUET, FSGS, Nephrotic Syndrome, News, patients, Research, Research News, Retrophin, Sparsentan, Treatments, Volunteer

Our Mission

NephCure Kidney International’s ® mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases.

Sign up for our emails »

NephCure Kidney International

  • Contact Us
  • Donate
  • Careers
  • Financials
  • Policy and Disclaimers

SHORT ON TIME?

Contact Information

150 S. Warner Road
Suite 402
King of Prussia, PA 19406
1.866 NephCure (637-4287)
info@nephcure.org
EIN: 38-3569922

Follow Us

  • Facebook
  • Twitter

© Copyright 2021 NephCure Kidney International, Inc. All rights reserved worldwide. NephCure Kidney International, and the logo, are federally registered trademarks of NephCure Kidney International, Inc.

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in